Paclitaxel-eluting resorbable scaffold - 480 Biomedical

Drug Profile

Paclitaxel-eluting resorbable scaffold - 480 Biomedical

Alternative Names: Paclitaxel-eluting stent - 480 Biomedical; Stanza DRS

Latest Information Update: 01 Aug 2016

Price : $50

At a glance

  • Originator 480 Biomedical
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Peripheral arterial disorders

Most Recent Events

  • 01 Aug 2016 Paclitaxel-eluting resorbable scaffold is still in phase III trials for Peripheral arterial disorders in Austria, Germany, New Zealand and Switzerland (Intra-arterial) (NCT02097082)
  • 15 Mar 2016 Biomarkers information updated
  • 31 Oct 2013 Phase-III clinical trials in Peripheral arterial disorders in Austria, Germany, New Zealand and Switzerland (Intra-arterial)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top